GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in popularity over the past few ...

Join a real-time written chat with WSJ’s Bradley Olson on Monday, March 24, from 3 p.m. to 4 p.m. ET. WSJ subscribers can ...

I’m one of the millions of people trying to keep the weight off without taking expensive drugs like Mounjaro or Ozempic for ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Experts aren’t really on board with taking these new, buzzy, multi-ingredient supplements that claim to help with insulin resistance. However, a few vitamin and mineral supplements do have some ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

In India, around 101 million people suffer from diabetes. More than half of these patients do not have their blood sugar ...

We recently published a list of 8 Best Robinhood Stocks to Buy According to Analysts. In this article, we are going to take a ...